Valuation : Mendus AB

Market Cap 487M 50.66M 43.7M 41.17M 37.51M 70.11M 4.79B 70.64M 189M 2.45B 190M 186M 8.04B P/E 2026 *
-4.83x
P/E 2027 * -7.33x
Enterprise Value 509M 52.87M 45.61M 42.97M 39.15M 73.18M 4.99B 73.73M 197M 2.55B 199M 194M 8.39B EV / Sales 2026 *
66.6x
EV / Sales 2027 * 1.83x
Free-Float
36.17%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week+3.52%
Current month+5.14%
1 month+11.52%
3 months+41.54%
6 months+81.50%
Current year+31.43%
1 week 6.87
Extreme 6.87
8.49
1 month 6.4
Extreme 6.4
8.49
Current year 3.86
Extreme 3.86
8.49
1 year 3.86
Extreme 3.86
9.37
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 76 13/12/2019
Chief Executive Officer 54 16/03/2021
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
28/2/22 Buy

Chief Technology Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+3.52%+4.55%+16.09% 50.66M
+0.62%-0.27%+2.84%+18.47% 50.14B
-0.30%-2.88%+429.29%+496.95% 44.85B
+2.13%+0.89%+43.59%+17.61% 43.43B
+0.87%-3.73%+8.96%+73.17% 41.14B
-0.90%-3.67%+14.26%+48.44% 32.92B
+2.71%+6.82% - - 17.56B
+1.68%-4.20%+25.28%+116.83% 16.55B
+2.14%+1.84%+18.26%+30.83% 14.65B
+3.34%-1.13%+80.94%+39.19% 13.93B
Average +1.10%-0.16%+69.77%+95.29% 27.52B
Weighted average by Cap. +0.76%-1.21%+92.91%+122.31%

Financials

2026 *2027 *
Net sales 7.63M 793K 684K 645K 587K 1.1M 74.95M 1.11M 2.96M 38.32M 2.98M 2.91M 126M 172M 17.89M 15.44M 14.54M 13.25M 24.77M 1.69B 24.95M 66.82M 864M 67.19M 65.72M 2.84B
Net income -99.17M -10.31M -8.89M -8.38M -7.63M -14.27M -974M -14.37M -38.49M -498M -38.71M -37.86M -1.64B -33.34M -3.47M -2.99M -2.82M -2.57M -4.8M -327M -4.83M -12.94M -167M -13.01M -12.73M -550M
Net Debt 21.31M 2.22M 1.91M 1.8M 1.64M 3.07M 209M 3.09M 8.27M 107M 8.32M 8.14M 351M -172M -17.88M -15.42M -14.53M -13.24M -24.74M -1.69B -24.93M -66.75M -863M -67.13M -65.66M -2.84B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
03/09/26 SEK 7.360 +0.14% 20,611
02/09/26 SEK 7.350 +2.94% 18,245
01/09/26 SEK 7.140 +2.00% 89,422
31/08/26 SEK 7.000 -0.57% 15,767
28/08/26 SEK 7.040 -0.98% 16,095
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.350SEK
Average target price
33.95SEK
Spread / Average Target
+361.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock